Porton Pharma Solutions (300363) Fundamentals 2026 — P/E 66.0x, Revenue Analysis | SniperIQ
Porton Pharma Solutions (300363) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥9.1B, trading at ¥16.66 on the SHZ. This SniperIQ fundamentals page covers Porton Pharma Solutions's valuation (P/E 66.0x, P/B 1.7x), profitability (net margin 3.7%), revenue (¥3.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Porton Pharma Solutions's market cap?
Porton Pharma Solutions (300363) has a market capitalization of approximately ¥9.1B, trading at ¥16.66 on the SHZ. Market cap moves with the live share price.
What is Porton Pharma Solutions's P/E ratio?
Porton Pharma Solutions's trailing twelve-month P/E ratio is 66.0x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Porton Pharma Solutions?
Porton Pharma Solutions runs a net profit margin of 3.7%, a gross margin of 30.3%, and an operating margin of 3.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Porton Pharma Solutions generate?
Porton Pharma Solutions reported revenue of ¥3.4B for fiscal year 2025, with net income of ¥96M and earnings per share (EPS) of 0.18. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Porton Pharma Solutions pay a dividend?
Porton Pharma Solutions offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Porton Pharma Solutions financially healthy?
Porton Pharma Solutions carries a debt-to-equity ratio of 0.34x and a current ratio of 1.85x, with a market beta of 0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Porton Pharma Solutions a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Porton Pharma Solutions (300363) the key facts are: market cap ¥9.1B, P/E 66.0x, revenue ¥3.4B, 52-week range 13.24-30.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Porton Pharma Solutions's full fundamentals live
Get Porton Pharma Solutions's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.